The global seasonal influenza vaccine market could reach $ 6.5 bn. by 2028. At the end of 2018, the seasonal influenza vaccine across the eight major markets was estimated at $ 4.6 billion. According to GlobalData, the analytical company, moderate growth is expected over the next 10 years on average by 3.7% annually, and by the end of 2028, this market could increase to $ 6.5 billion.
The report “Seasonal Influenza: Global Drug Forecast and Market Analysis to 2028” notes that the launch of new, more expensive, but potentially more effective vaccines will be the main growth factor in the influenza vaccine market.
The analysts predict that over the next decade, the sale of quadrivalent influenza vaccines Flucelvax and Flublok will show significant growth.
Some experts believe that the universal influenza vaccine will become available on the market within the next 5 years; while others are convinced that necessary clinical trials will take a bit longer period.